The pressure injectable M/29 Midterm catheter series is the latest addition to Flexicath’s M/29 family of midline catheters.
The company describes the M/29 Midterm as “the world’s first IV catheter solution to provide a ‘built in’ 360-degree Maximum Barrier against airborne and touch-borne contamination during the insertion process and offers a simple to place intermediate dwell alternative for patients needing IV therapy for less than 30 days,” in the release.
Flexicath is headquartered in Pittsburgh.
Related Articles on FDA Clearances:
Hollywog Receives FDA Clearances for Remote Controlled Back Pain Devices
Toshiba Receives FDA Clearance for Vantage Titan 1.5T MRI
Covalon Receives FDA Clearance for Antimicrobial Silicone Wound Dressing
